Related Experiment Video
Updated: Jan 10, 2026
04:48
Establishing a Severe Corneal Inflammation Model in Rats Based on Corneal Epithelium Curettage Combined with Corneal Sutures
Published on: November 22, 2024
746
Mooren's ulcer: a multifactorial autoimmune peripheral ulcerative keratitis and current treatment protocols
Shangkun Ou1,2,3,4, Yujie Zhang2, Yuchong Feng4
1Department of Ophthalmology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Frontiers in Medicine
|November 27, 2025
Summary
Mooren's Ulcer (MU), a painful autoimmune eye condition, lacks clear diagnostic criteria. This review proposes a structured diagnostic framework using lab tests and immunological strategies for better differential diagnosis and treatment.
Area of Science:
- Ophthalmology
- Immunology
- Autoimmune Diseases
Background:
- Mooren's Ulcer (MU) is a rare, chronic, autoimmune peripheral ulcerative keratitis (PUK) with unknown causes.
- Diagnosis relies on exclusion, and standardized criteria/treatments are lacking.
- MU poses risks of corneal perforation and vision loss.
Purpose of the Study:
- To present a structured diagnostic framework for Mooren's Ulcer.
- To emphasize laboratory and immunological testing for differential diagnosis.
- To review current knowledge on MU epidemiology, etiology, pathology, classification, and treatment.
Main Methods:
- Comprehensive literature review.
- Systematization of diagnostic components, including lab and immunological tests.
- Discussion of advanced imaging, histopathology, and tear markers.
Main Results:
- A structured diagnostic framework for MU is proposed.
- Emphasis on laboratory and immunological testing for accurate diagnosis.
- Review of evolving diagnostic and monitoring tools.
Conclusions:
- A tiered, individualized treatment approach is recommended for Mooren's Ulcer.
- Advocacy for multicenter studies to validate diagnostic protocols.
- Need for evidence-based clinical guidelines for MU management.
Related Concept Videos
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K
01:28Peptic Ulcer Disease II: Pathophysiology
1.9K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.9K
01:26Peptic Ulcer Disease IV: Management
406
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
406
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.0K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.0K
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
507
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
507